Ocunexus Therapeutics is a Development stage biopharmaceutical company with novel, proven gap junction channel modulation technologies targeting unmet clinical needs in ophthalmology
Over 23 million Americans are afflicted with sight-threatening disease. The leading causes of blindness and low vision in the USA are age-related and diabetic eye diseases, including back-of-the-eye-disorders such as age-related macular degeneration, diabetic retinopathy and diabetic macular edema. Worldwide, the projected number of people with age-related macular degeneration alone by 2020 will be 196 million, increasing to 288 million in 2040.
OcuNexus Therapeutics has highly differentiated, lead drug candidates based upon a novel mechanism of action called “Gap Junction Channel Modulation.” OcuNexus has potential treatments for multiple front- and back-of-the-eye diseases and disorders, and is developing unique, patented therapeutics to treat ophthalmic diseases with high unmet needs that offer the potential to alter the standard of care. In addition, the company's technologies are expected to be transferable to other acute and chronic disease indications.
This website is designed to provide an overview of our company's technology, clinical objectives, and human resources. We welcome inquiries from potential clinical and business collaborators.